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Objectives: We conducted a systematic review and meta-analysis to summarize the clinical evidence and
usage patterns of intravenous fosfomycin from its development to the present time.
Methods: PubMed, the Cochrane Library and local journals were searched for relevant studies reporting
aggregated data of intravenous fosfomycin use in adults and children, with no restrictions regarding
study design. Single case reports were excluded. Data were systematically abstracted for all included
studies. Clinical and microbiological efﬁcacy from randomized controlled and comparative observational
studies were synthesized using meta-analysis to calculate pooled effect sizes.
Results: In all, 128 studies on intravenous fosfomycin in 5527 patients were evaluated. Fosfomycin was
predominantly used for sepsis/bacteraemia, urinary tract, respiratory tract, bone and joint, and central
nervous system infections. No difference in clinical (OR 1.44, 95% CI 0.96e2.15) or microbiological (OR
1.28, 95% CI 0.82e2.01) efﬁcacy between fosfomycin and other antibiotics was observed in comparative
trials. The pooled estimate for resistance development during fosfomycin monotherapy was 3.4% (95% CI
1.8%e5.1%). Fosfomycin showed a favourable safety proﬁle, with generally mild adverse events not
requiring discontinuation of treatment. Included studies explored intravenous fosfomycin as an anti-
staphylococcal agent in monotherapy and combination therapy, whereas studies from 1990 focused on
combination therapy (fosfoymcin þ b-lactams or aminoglycosides) for challenging infections frequently
caused by multidrug-resistant organisms.
Conclusion: Intravenous fosfomycin can play a vital role in the antibiotic armamentarium, given its long
history of effective and safe use. However, well-designed randomized controlled trials are still desired.
B. Grabein, Clin Microbiol Infect 2017;23:363
© 2016 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and
Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Fosfomycin is a broad-spectrum, bactericidal antibiotic discov-
ered in 1969 [1]. It is the sole member of the epoxide group of an-
tibiotics and inhibits peptidoglycan formation at an earlier step than
b-lactams. Intravenous fosfomycinwas initially registered in varioustoPharm Arzneimittel und
ppenheim, Germany.
(D.B. Liesenfeld).
Ltd on behalf of European Society
g/licenses/by-nc-nd/4.0/).European (Spain, Germany, France) and non-European (Japan)
countries. The clinical use of intravenous fosfomycin has remained
at relatively constant but low levels. Interest in intravenous fosfo-
mycin has renewed in the twenty-ﬁrst century, as it remains active
against many problematic pathogens such as methicillin-resistant
Staphylococcus aureus (MRSA) [2], glycopeptide-resistant entero-
cocci [3,4], and multidrug-resistant (MDR) enterobacteria [5]. Fos-
fomycin is active against a wide range of Gram-positive and Gram-
negative species, but shows only very limited activity against
anaerobic species, most importantly Bacteroides, as well as against
selected Gram-negative species such as Acinetobacter baumannii orof Clinical Microbiology and Infectious Diseases. This is an open access article under
B. Grabein et al. / Clinical Microbiology and Infection 23 (2017) 363e372364Burkholderia spp. [6,7]. Fosfomycin is regarded as an antibiotic with
attractive pharmacokinetic properties, explaining its potential value
in complicated and frequently deep-seated infections such as in-
fections of the central nervous system (CNS) [8,9], bone and joints
[10], lungs [11], and soft tissues [12], as well as sepsis [13,14].
Development of resistance to fosfomycin is a concern, but the clin-
ical relevance and determinants are not well understood. This re-
view aims to summarize the available evidence on intravenous
fosfomycin. Furthermore, inclusion of clinical reports from the
developmental era of fosfomycin will make these publications
globally available for the ﬁrst time. This study will also describe
clinical patterns of intravenous fosfomycin use and help to identify
gaps for future clinical research.
Materials and methods
Identiﬁcation of studies
We searched PubMed and the Cochrane Library without any
language restrictions until July 2016 to identify studies on human
clinical exposure to intravenous fosfomycin. Electronic search
strategies are provided in the Supplementary material (Data S1).
Additionally, we identiﬁed records by a hand search of local jour-
nals not indexed in the above-mentioned medical databases.
Inclusion criteria and study selection
Only studies reporting aggregated data of intravenous fosfo-
mycin use in patients were included. Studies reporting on intra-
venous use in addition to other routes of administration were also
included, but data abstracted separately by each route of admin-
istration, if possible. Single case reports, animal studies and in vitro
data were excluded. The following treatment indications were
accepted: osteomyelitis, meningitis, encephalitis, cerebral abscess,
urinary tract infections (UTI), respiratory tract infections (RTI),
pulmonary abscesses, perioperative infections, skin infections, soft-
tissue infections, burn-associated infections, diabetic foot in-
fections, intra-abdominal infections, sepsis/bacteraemia, endo-
carditis, and ear, nose and throat infections.
Data extraction
The following data were abstracted from the full texts of
included articles: study design, number of patients treated with
fosfomycin, patients' age and gender, treatment indication(s),
monotherapy or combination therapy (at least 1 day of dual ther-
apy), duration of treatment, control group (for comparative
studies), mean daily dose of fosfomycin (an adult body weight of
70 kg was assumed for conversion from doses in g to doses in mg/
kg), clinical efﬁcacy (evaluated according to the deﬁnitions used in
each individual study), organisms isolated, microbiological efﬁcacy,
and development of resistance (as per deﬁnition of individual au-
thors) during fosfomycin monotherapy, as well as safety data. For
each continuous variable, the mean ± standard deviation was
weighted by the number of patients to take account of study sizes.
Quality assessment
Due to the broad inclusion criteria and scope, a high level of
heterogeneity between studies was anticipated. Non-comparative
studies (inherently high risk of bias) were therefore not assessed
for quality and not used for meta-analysis. Quality of comparative
trials (randomized controlled and comparative observational
studies) was assessed using a grading scheme by the National
Institute of Health (NIH) (http://www.nhlbi.nih.gov/health-pro/guidelines/in-develop/cardiovascular-risk-reduction/tools/rct). Ac-
cording to the scheme, various parameters of quality such as pres-
ence andmethod of randomization, treatment allocation, single and
double blinding, absence of differences in patient populations,
overall and differential dropout rate, protocol adherence, similar
background interventions, outcome assessment, sample size, pre-
speciﬁed subgroup analysis and intention-to-treat analysis were
checked. Studies earned one point for the presence of each quality
criterion andwere graded as poor (1e4 points), poorefair (5 points),
fair (6e8 points), fairegood (9 points) or good (10e14 points) by
three independent assessors (BG, WG, DBL). In case of non-
agreement, all the assessors discussed studies to reach consensus.
Data analysis and statistics
Analysis of clinical and microbiological efﬁcacy (meta-ana-
lysis). Only data from studies comparing fosfomycin against other
antibiotics were included into a meta-analysis (random effects
model) of clinical andmicrobiological efﬁcacy using OR as the effect
size estimate. Odds ratios >1 favoured fosfomycin therapy. Only
crude effect sizes were used, as studies did not report on adjusted
efﬁcacy outcomes. To assess the effect of study quality on outcomes,
we performed a sensitivity analysis including all comparative trials
versus trials with poor quality excluded. Additionally, an explor-
atory analysis was conducted to explore associations of covariates
with clinical efﬁcacy (see Supplementary material, Data S2).
All analyses were carried out in the statistical software R 3.3.1.
The METAFOR package was used to run meta-analyses and meta-
regressions [15].
Analysis of safety data. All studies reporting adverse reactions
were included into analysis of safety data. Adverse events were
abstracted and rated as non-serious or serious as per listing on the
EudraVigilance Expert Working Group Important Medical Events
list version 18.1.
Results
Of 559 records identiﬁed by systematic literature search, 128
studies fulﬁlled the inclusion criteria and were subject to review
and systematic data abstraction (see Fig. 1). Studies excluded at the
abstract or full text stages were mostly single case reports or re-
ported on oral fosfomycin only (see Supplementary material, Data
S3 for a full list studies and abstracted data).
Patterns of clinical use
Patient population. The 128 studies included 5527 patients
treated with intravenous fosfomycin. Most studies originated from
France (n ¼ 38), Germany and Austria (n ¼ 31), Japan (n ¼ 24) or
Spain (n ¼ 20). A majority of the studies (n ¼ 84) were published
before 1989, i.e. before the formal adoption of EU guidelines on
good clinical practice. Twenty-eight of the 128 studies (21.9%)
exclusively reported on paediatric populations (n ¼ 819) [16e43].
Seven case series reported exclusively on newborns and infants
receiving fosfomycin for neonatal sepsis, meningitis or severe UTI.
Fifteen additional studies included both children and adults
[44e58]. Seven studies focused on the use of fosfomycin in patients
with haematological malignancies [18,30,59e63].
Quality of studies. Almost half of the reports (61/128; 48%) were
retrospective case series and only a minority of studies were
comparative (six non-randomized controlled trials and three case-
control studies; 9/128; 7%) or randomized controlled (8/128; 6%).
Comparative studies scored an average of 6/14 quality points, indi-
cating low to average quality, with high variability across studies (see
Table 1 and see Supplementary material, Data for individual scores).
Fig. 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) ﬂowchart describing the search strategy.
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procedures, adequate description of randomization procedures or
treatment allocation, and appropriate measures to control for
possible confounding factors (observational studies).
Indications and isolated pathogens. More than 75% of all pa-
tients (4279/5527; 77%) were treated for ﬁve main indications,
sepsis/bacteraemia, RTI (mostly pneumonia), UTI, bone/joint in-
fections (mostly osteomyelitis) and CNS infections (Fig. 2a).
A total of 3495 pathogens were isolated in all studies combined.
Fosfomycin was most often used against staphylococci (1408 iso-
lates), predominantly Staphylococcus aureus (1062 isolates), Escher-
ichia coli (544 isolates), Pseudomonas spp. (465 isolates),
Streptococcus spp. (252 isolates) and Klebsiella spp. (218 isolates)
(Fig. 2b). Fourteen studies placed emphasis on pathogens with pre-
existing resistance to various antibiotic classes such as MRSA or
methicillin-resistant Staphylococcus epidermidis [14,75,77e82] or
carbapenem-resistant and MDR Gram-negative species (resistance
status reported as deﬁned by the respective authors)
[44,67,74,83e85]. Studies on MDR Gram-negative species were all
published after 2010.
Dosing and therapy regimens. Fosfomycin dosing, averaged
over all patients, varied considerably across studies and countries.
Dosing in Europe was consistent, with average daily doses of
181 mg/kg (12.7 g) for France, 182 mg/kg (12.7 g) for Germany/
Austria, and 220 mg/kg (15.7 g) for Spain, typically divided into two
or three equal doses. In contrast, dosing was much lower in Japan,
with an average of 56 mg/kg (3.9 g) per day. Few studies reported
on high-dose (>20 g / >285 mg/kg) treatment [20,32,57,85e87].
With respect to paediatric populations, authors reported daily
doses based on body weight, mostly in the range 100e200 mg/kg
(lowest: 50 mg/kg; highest: 500 mg/kg).
More studies reported on fosfomycin combination therapy (73
studies, 2675 patients) than monotherapy (44 studies, 1757patients).Monotherapywas used for allmajor indications, though in
osteomyelitis and UTI fosfomycin was used as monotherapy in a
greater proportion of patients (604/1693 patients; 36%) than com-
bination therapy (388/2493 patients; 16%). Monotherapy studies
were almost exclusively published before 1990; studies on combi-
nation therapy thereafter (see Supplementary material, Fig. S1).
Combination therapywasmost often implementedwith a b-lactam,
i.e. cephalosporins (1066 patients), penicillins (533 patients), car-
bapenems (150 patients), or an aminoglycoside (254 patients).
Clinical efﬁcacy
Ten studies (seven randomized) comparing the clinical efﬁcacy of
intravenous fosfomycinagainstother antibioticswere included into a
meta-analysis, corresponding to 315 patients treated with fosfomy-
cin. We did not observe a difference in clinical efﬁcacy between
fosfomycin and respective comparators (OR 1.44, 95% CI 0.96e2.15)
irrespective of monotherapy (OR 1.41, 95% CI 0.83e2.39) or combi-
nation therapy (OR 1.48, 95% CI 0.81e2.71). The same results were
obtained when studies with poor quality were excluded (OR 1.45,
95% CI 0.94e2.24). Among the six studies with fair or good study
quality, fosfomycin combination therapy was used against RTIs/
pneumonias (three of three studies). Monotherapy was used against
UTIs (two or three studies), or RTIs (one study of three). No hetero-
geneity was observed in any meta-analyses (Fig. 3). For exploratory
analyses see Supplementary material and Tables S2eS3.
Microbiology
Microbiological efﬁcacy. The study of Albano et al. did not report
any microbiological efﬁcacy data and was therefore excluded [72].
Pooled analysis of the remaining nine comparative studies did not
indicate anydifference between fosfomycin and its comparators (OR
Table 1
Summary of studies comparing intravenous fosfomycin therapy (either monotherapy or combination) against another therapy regimen
Author, yr, country Design Patients, n Infection Isolated pathogens Fosfomycin treatment Comparator Clinical cure Microbio. cure Quality
Sano, 1979 [64],
Japan
RCT 107, adults UTI Pseudomonas spp. (mostly
Pseudomonas aeruginosa), Proteus
spp. (mostly Proteus mirabilis)
2  2 g/day fosfomycin 2  2g/day sulbencillin 33/57 (56%) vs. 27/
50 (54%)
23/57 (40%) vs. 20/50
(40%)
Good
Kobashi, 2002 [65],
Japan
RCT 41, adults Moderate
pneumoniad
Klebsiella pneumoniae (4),
Streptococcus pneumoniae (4),
MSSA (4), P. aeruginosa (3), MRSA
(2), Klebsiella oxytoca (2),
Haemophilus inﬂuenzae,
Enterococcus cloacae, Serratia
marcescens, Streptococcus milleri,
Acinetobacter baumannii (1 each)
2  2 g/day fosfomycin þ
2  1 g/day sulbactam/
cefoperazone
2  1 g/day sulbactam
cefoperazone
17/18 (94%) vs. 15/
17 (88%)
5/10 (50%) vs. 5/9 (56%) Fair-
good
Shimokata, 1988
[66], Japan
RCT 53, adults RTI (mostly
pneumonia)
H. inﬂuenzae (4), K. pneumoniae
(3), Staphylococcus aureus (2),
S. agalactiae (2), Streptococcus
viridans (2), Klebsiella sp.,
P. aeruginosa, Staphylococcus
epidermidis, Haemophilus
parainﬂuenzae, Enterococcus
faecium, Enterobacter aerogenes,
Streptococcus pneumoniae (1 each)
2  1-2g/day
fosfomycin þ 2  1e2 g/
day cefotaxime
cefotaxime 33/41 (80%) vs. 27/
32 (84%)
10/11 (91%) vs. 4/4
(100%)
Poor-
fair
Hiraoka, 1996 [61],
Japan
RCT
(Supplement)
161, age: NA Bacteraemia/
SepsisPneumonia
Not reported 2 2 g/day fosfomycin þ
2  1e2g/day sulbactam/
cefoperazone
Sequence 1: Fos -> Sul
CefSequence
2: Sul/Cef -> Fos
45/76 (59%) vs. 30/
69 (43%)
Not reported Poor-
fair
Sirijatuphat, 2014
[67], Thailand
RCT 104, adults A. baumannii
infections (78%
pneumonia)
Carbapenem-resistant
A. baumannii
2  4 g/day
fosfomycin þ 5 mg/kg/
day colistin (base activity)
5 mg/kg/day colistin (b
activity)
30/47 (64%) vs. 27/
47 (57%)
47/47 (100%) vs. 38/47
(81%); p 0.01
Fair-
good
Ode, 1988 [68],
Sweden
RCT 38, adults Pyelonephritis Escherichia coli (30), Klebsiella spp.
(2), Proteus vulgaris, P. aeruginosa,
Staphylococcus aureus,
Enterococcus sp. (1 each)
2  8 g/day fosfomycina 3  2 g ampicillin 7/16 (44%) vs. 6/22
(27%)
7/16 (44%) vs. 6/22
(27%)
Fair
Nissen, 1986 [69],
Denmark
RCT 32, adults Severed acute
pneumonia
Coagulase neg. staphylococci (9),
Streptococcus pneumoniae (6),
Streptococcus spp. (4), Moraxella
catarrhalis (4), Escherichia coli (7),
K. pneumoniae (4), Haemophilus
inﬂuenzae (2), Enterococcus
cloacae (1), P. aeruginosa (3)
3  4 g/day fosfomycin þ
3  80 mg gentamicinb
4  1 g/day ampicillin
3  80 mg gentamicin
10/17 (59%) vs. 7/15
(47%)
87.5% vs. 90% (no
absolute numbers)
Fair
Zhang, 2003 [70],
China
RCT 118, adults lower RTId Streptococcus pneumoniae (18),
K. pneumoniae (17), Escherichia
coli (16), Staphylococcus
epidermidis (9), Haemophilus
verdigris (9), Staphylococcus
haemolyticus (8), P. aeruginosa (7),
Staphylococcus aureus (3),
Acinetobacter spp. (3)
8 g/day fosfomycin 4 g/day ceftriaxone 49/59 (83%) vs. 45/
59 (76%)
75/90 (83%) vs. 68/85
(80%)
Fair
Otsuka, 1994 [71],
Japan
Non-
randomized
controlled
study
47, adults (15
cancer patients)
Primarily RTI
(50% pneumonia)
MRSA (23), MRSA þ secondary
pathogen (39). Secondary
pathogens: P. aeruginosa (14),
K. pneumoniae (5), Enterococcus
spp. (5) and others
2  2-4 g/day
fosfomycin þ 2  2g/day
cefmetazole
2  2-4 g/day fosfomy
2  2 g/day ﬂomocef
16/22 (73%) vs. 14/
22 (64%)
11/22 (50%) vs. 11/25
(44%)
Poor-
fair
Albano, 1978 [72],
Italy
Caseecontrol
study
64, pregnant
women
Obstetric
infections
Not reported fosfomycin (dose not
reported)
cefapirin (dose not
reported)
35/38 (92%) vs. 22/
26 (85%)
Not reported Poor
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Baron, 1987 [73],
France
Caseecontrol
study
35, adults and
children
primarily sepsis MSSA 237 mg/kg/day
fosfomycin þ 145 mg/kg/
day Penicillin M
3.6 mg/kg/day
gentamycin þ 113 mg/kg/
day Penicillin M
16/17 (94%) vs. 14/
18 (78%)
same as clinical Poor-
fair
Apisarnthanarak,
2012 [74],
Thailand
Caseecontrol
study
49, adults HAP, VAP Carbapenem resistant
P. aeruginosa
Fosfomycin þ Doripenem
(dose not reported)
Fosfomycin þ Colistin (dose
not reported)
15/25 (60%) vs. 14/
25 (56%)
18/25 (72%) vs. 15/24
(63%)
Poor
Matsumoto, 1993
[75], Japan
Non-
randomized
controlled
study
19, adults UTI, wound
infections
MRSA Fosfomycin þ Cefuzonam
(dose not reported)
Minocycline þ Cefuzonam
(dose not reported)
5/5 (100%) vs. 4/7
(57%)
same as clinical Poor
Guerrero, 1986
[76], Spain
Caseecontrol
study
40, adults and
children
Osteomyelitis Staphylococcus aureus (33),
Staphylococcus epidermidis (4),
Escherichia coli (2), Enterococcus
faecalis (2), Serratia marcescens
(2), Mycobacterium tuberculosis
(2), Proteus mirabilis, Citrobacter
diversus, Pseudomonas ﬂuorescens,
Klebsiella oxitoca, Citrobacter
freundii, P. aeruginosa (1 each)
150e200 mg/kg/day
fosfomycina
150e200 mg/kg/day
fosfomycin þ various other
antibioticsa
16/20 (80%) vs. 16/
20 (80%)
19/20 (95%) vs. 18/20
(90%)
Poor
Corti, 2003 [21],
Switzerland
Caseecontrol
study
70, children Osteomyelitis Staphylococcus aureus (12),
Coagulase negative Staphylococci
(6), Streptococcus pyogenes (2),
Streptococcus pneumoniae (1)
200 mg/kg/day
fosfomycin (mono)
Comparator 1c: 200 mg/kg/
day fosfomycin þ various
combination partners
Comparator 2: Various
antibiotics
Only C reactive
protein value given
over time as
measure of
response.
Comparable in all
groups.Duration of
treatment shorter
in fosfomycin
monotherapy
(p < 0.05)
Not reported poor
Abbreviations: UTI, urinary tract infections; RTI, respiratory tract infections; HAP, hospital-acquired pneumonia; VAP, ventilator-associated pneumonia; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-
sensitive Staphylococcus aureus.
a Resistance development of one strain was noted during treatment (fosfomycin or comparator, respectively).
b Resistance development of four strains were noted during fosfomycin combination therapy.
c Resistance development of two strains were noted during fosfomycin combination therapy.
d Severity of diseases was not systematically reported by the authors. Indications are presented as per deﬁnitions of the respective authors.
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Fig. 2. Descriptive summary of the studies reviewed here. (a) Numbers of patients treated with intravenous fosfomycin by treatment indication as per MedDRA version 19.0. BJI,
bone and joint infections; UTI, urinary tract infections; CNS, central nervous system infections; SSTI, skin and soft-tissue infections. (b) Absolute numbers of microbiological isolates
reported by pathogen.
B. Grabein et al. / Clinical Microbiology and Infection 23 (2017) 363e3723681.28, 95% CI 0.82e2.01). Detailed, pooled analysis based on the un-
derlying pathogens was not possible, because most authors did not
report microbiological efﬁcacy at the individual pathogen level.
However, Matsumoto et al. and Baron et al. reported on S. aureus
(methicillin-susceptible and MRSA, respectively) indicating virtu-
ally complete eradication [73,75]. Sano et al. provided pathogen-
speciﬁc data on eradication rates for Pseudomonas spp. (47.2%; 17/
36) and Proteus spp. (75%; 21/28) [64]. Sirijatuphat and Thamlikitkul
reported signiﬁcantly higher microbiological efﬁcacy of a combi-
nation of fosfomycin þ colistin compared with colistin alone (100%
versus 81.2%, p 0.01) for the eradication of carbapenem-resistant
A. baumannii [67].
Development of resistance (monotherapy). Fifteen monotherapy
studies assessed the development of resistance towards fosfomycinFig. 3. Clinical efﬁcacy in patients who were treated with intravenous fosfomycin compared
with fosfomycin. Diamonds indicate pooled ORs (± 95% CI).during monotherapy (see Supplementary material, Table S1). One
study included data on patients receiving oral or parenteral fosfo-
mycin without data stratiﬁcation so was excluded from analysis
[48]. The remaining studies reported different levels of emergence
of resistance ranging from single isolates to 17.9% [49,57,68,88e97].
The pooled estimate for resistance development during fosfomycin
monotherapy was 3.4% (95% CI 1.8%e5.1%).
Safety
Seventy-two of 128 studies (56%) reported safety data, including
480 adverse events in 2672 treated patients (18.0%; Table 2). The
most common adverse events included gastrointestinal distress
(nausea, vomiting, alterations of taste and diarrhoea: 140 events;with other antibiotic agents. Odds ratios (ORs) > 1 indicate increased clinical efﬁcacy
Table 2
List of adverse events reported with intravenous fosfomycin use, categorized by
their MedDRA preferred and high level terms
Adverse event No.
occurrence
Relative
occurrence (%)
Gastrointestinal disorders 140 5.24
Gastrointestinal disorders (unspeciﬁed) 69 2.56
Diarrhoea 16 0.60
Nausea 13 0.49
Dysgeusia 31 1.16
Vomiting 9 0.34
Abdominal pain 1 0.04
Retching 1 0.04
Metabolism and nutrition disorders 99 3.71
Hypokalaemia 78 2.92
Hypernatraemia 18 0.68
Decreased appetite 1 0.04
Skin and subcutaneous tissue disorders 23 0.86
Rash 19 0.71
Rash morbilliform 2 0.07
Urticaria 1 0.04
Erythema multiforme 1 0.04
Injury, poisoning and procedural
complications
27 1.01
(Thrombo)phlebitis 16 0.60
Venous intolerance 11 0.41
Altered laboratory parameters 103 3.85
Hepatic enzyme increased (unspeciﬁed) 59 2.21
Transaminases increased (unspeciﬁed) 20 0.75
Alanine aminotransferase increased 5 0.19
Laboratory test abnormal (unspeciﬁed) 5 0.19
Blood alkaline phosphatase increased 5 0.19
Aspartate aminotransferase increased 3 0.11
Blood bilirubin increased 2 0.07
Blood urea increased 2 0.07
Blood creatinine increased 1 0.04
Respiratory rate increased 1 0.04
Blood and lymphatic system disorders 19 0.71
Leukopenia* 6 0.22
Anaemia 5 0.19
Thrombocytopenia 4 0.15
Neutropenia* 3 0.11
Eosinophilia 1 0.04
General disorders and administration
site conditions
19 0.71
Oedema 6 0.22
Asthenia 4 0.15
Hyperhydrosis 3 0.11
Injection site pain 3 0.11
Pyrexia 1 0.04
Nicolau syndrome*,a 1 0.04
Flush 1 0.04
Infections and infestations 6 0.22
Systemic candidiasis* 2 0.07
Fungal infection 2 0.07
Herpes simplex infection 2 0.07
Nervous system disorders 16 0.60
Headache 14 0.52
Vertigo 1 0.04
Hyperosmolar coma* þ hyperglycaemia 1 0.04
Vascular disorders 5 0.19
Hypertension 2 0.07
Vascular pain 2 0.07
Shock* 1 0.04
Cardiac disorders 9 0.34
Tachycardia 3 0.11
Cardiac failure*,b 2 0.07
Pain in the heart* 2 0.07
Cardiac disorders (unspeciﬁed) 2 0.07
Other 16 0.60
Worsening of pulmonary oedema*
in patients with heart insufﬁciency
and endocarditis
2 0.07
Cough 1 0.04
Table 2 (continued )
Adverse event No.
occurrence
Relative
occurrence (%)
Abnormal Fishberg test 1 0.04
Conjunctivitis 1 0.04
Flushing 1 0.04
Unspeciﬁed side effects 10 0.37
Relative number of occurrences is derived from the total number of studies for
which adverse events have been reported (total patient number: 2672).
* Adverse events are classiﬁed as serious based on their listing on the important
medical events (IME) list of the EudraVigilance Expert Working Group version 18.1.
a 1) Nicolau syndrome occurred in a patient which was treated with fosfomycin
intramuscularly.
b 2) Cardiac failure was noticed in 2 patients, one 84-year old man with a pre-
existing heart insufﬁciency, and one 75-year old women with a history of dia-
betes. Cardiac failure was attributed to fosfomycin, because differential diagnoses
were ruled out.
B. Grabein et al. / Clinical Microbiology and Infection 23 (2017) 363e372 3695.2%) and abnormal laboratory ﬁndings (predominantly transient
elevation of hepatic enzymes; 92 events; 3.4%). Hypernatraemia
and/or hypokalaemia were additional relevant adverse events (86
events; 3.6%). Only 18 events (<0.01%) were classiﬁed as serious
(Table 2), most commonly leukopenias (six events; <0.01%) or
neutropenias (three events; <0.01%). With respect to paediatric
patients, no differences were found in comparison with the overall
population in relation to reported adverse events rates, indicating
equally high tolerability in children.
Discussion
This systematic review reﬂects the clinical evidence base for
intravenous fosfomycin, summarizing the available published
literature, which consists of 128 studies including 5527 treated
patients. The main result of this review is the ﬁnding that intra-
venous fosfomycin did not show a different level of clinical or
microbiological efﬁcacy compared with other antibiotics against
which it was tested in comparative trials (primary outcome: OR).
Despite various different comparators (penicillins, cephalosporins
and aminoglycosides), indications and treatment regimens (mon-
otherapy/combination therapy), pooled results were robust with no
indication of heterogeneity or sensitivity towards study quality.
With respect to microbiological efﬁcacy, data stratiﬁed by the
causing pathogens was very scarce. Those studies providing
species-speciﬁc data indicated excellent efﬁcacy against S. aureus,
even in monotherapy, reafﬁrming the traditional perception of
fosfomycin as an anti-staphylococcal drug. High efﬁcacy against
A. baumannii was noted in combination with colistin, despite the
intrinsically low activity of fosfomycin against this pathogen. The
added effect can be explained by synergistic activity between fos-
fomycin and colistin [98]. Microbiological efﬁcacy against Pseudo-
monas aeruginosa in monotherapy seemed rather limited [64],
consistent with EUCAST guidance suggesting that combination
with other antibiotics is required for this pathogen [99]. Fosfomycin
was a well-tolerated drug, showing a favourable safety proﬁle with
serious adverse events being reported very infrequently. Adverse
events were generally mild and did not require discontinuation of
treatment. However, physicians should be aware of the risks of
hypernatraemia and/or hypokalaemia representing important side
effects requiring monitoring.
Our review additionally assessed fosfomycin's clinical usage
patterns: it is predominantly used in complex infections such as
sepsis/bacteraemia and respiratory, urinary tract, CNS, as well
as bone and joint infections. During its development period,
B. Grabein et al. / Clinical Microbiology and Infection 23 (2017) 363e372370fosfomycinwas primarily regarded as an anti-staphylococcal agent,
but more recent reports use it more often against MDR Gram-
negative species. This additional usage pattern reﬂects the rising
rates of bacterial resistance to anti-infective drugs worldwide and
is concordant with the consistently low antimicrobial resistance
rates for fosfomycin [5]. In addition to the targeted pathogens,
therapy schemes of intravenous fosfomycin have also dramatically
changed, resulting in a switch from monotherapy to combination
therapy. The present review shows that resistance emerged during
fosfomycin monotherapy at rates ranging from <3% to 17.9%
(pooled estimate 3.4%). This matches the rates reported for other
antibiotic classes (i.e. penicillins, aminoglycosides or carbapenems)
[100,101] as well as those reported by other authors for fosfomycin
[102]. Our results conﬁrm the generally noted discrepancy between
high rates of in vitro emergence of resistance and its evidently low
clinical relevance [102].
Limitations of our analysis are mostly inherent to the studies
included in the review, i.e. lack of appropriately statistically pow-
ered, prospectively collected, or comparative trials. Half of the few
randomized controlled trials included in our analysis (four of eight)
did not reﬂect current intravenous fosfomycin dosing schemes and
all lacked the statistical power of classical pivotal trials. Most of the
available data still come from retrospective case series, with the
corresponding intrinsic risk of bias. Heterogeneity of studies and
reporting quality restricted the possible options for data stratiﬁ-
cation. A risk of bias, particularly selection bias, may therefore
remain. Efﬁcacy endpoints (clinical and microbiological) were
applied using the deﬁnitions given in the respective studies and not
adjusted by the authors for potential confounders. The strength of
evidence presented in this review is consequently limited as well.
However, the limitations discussed have to be seen in the context of
the available data and the reporting standards decades ago. The
data presented in this review are therefore expected to provide an
accurate reﬂection of the past and current clinical use of intrave-
nous fosfomycin and the current clinical evidence.Conclusions and future outlook
The data presented here lead to the conclusion that fosfomycin
has comparable clinical efﬁcacy with other antibiotic classes and
has retained activity against MDR organisms. Fosfomycin therefore
has a place in the armamentarium of substances to combat chal-
lenging indications in the multidrug resistance era. Moreover, it
shows an overall favourable safety proﬁle. Sepsis/bacteraemia, and
respiratory tract, urinary tract, CNS, and bone and joint infections
were identiﬁed as the most important indications, combined with a
more recent trend towards the treatment of MDR Gram-negative
bacteria. Well-designed randomized controlled trials comparing
intravenous fosfomycin therapy with state-of-the-art ﬁrst-line
therapy alternatives are desired to conﬁrm the currently available
clinical evidence. Ongoing studies with fosfomycin in monotherapy
and combination therapy are addressing these questions with
respect to complicated or bacteraemic UTI and MRSA bacteraemia
[103,104]. Respiratory tract, CNS, and bone and joint infections are
identiﬁed as additional areas in which new studies of intravenous
fosfomycin may ﬁll gaps in clinical research.Transparency declaration
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